miR-106a mimics the nuclear factor-κB signalling pathway by targeting DR6 in rats with osteoarthritis
Luping Cui1, Yongbin Han2, Zhijie Dong3
1Department of Rheumatology and Immunology, Shanxi Provincial People's Hospital, Taiyuan, Shanxi Province, China.
Introduction:
Osteoarthritis (OA) is a common inflammatory joint disease characterised by progressive cartilage destruction. Management of this condition remains a significant challenge, and new therapies are required. We investigated the protective effects of miR-106a mimics in a murine model of OA.
Material And Methods:
This study was performed using both in vitro and in vivo OA models. Primary chondrocytes were isolated from female rats, with inflammation induced via treatment with lipopolysaccharide (LPS). Then the effects of a miR-106a mimic were examined based on the level of inflammatory cytokine production and apoptotic signalling following LPS stimulation. An in vivo rat model of OA was generated by injecting LPS into the anterior cruciate ligament, followed by treatment with miR-106a mimics. Then, inflammatory and apoptotic protein expression was assessed in the cartilage tissue.
Results:
Treatment with miR-106a mimic reduced the levels of inflammatory cytokines and apoptotic proteins in cartilage tissues following LPS-induced inflammation. Furthermore, the mimic ameliorated the expression of DR-6 mRNA and DR6, IκBα, and p65 proteins in chondrocytes. Similar effects were seen in the in vivo model, with the mimic attenuating expression of NF-κB, p65, IκBα, and DR6 proteins and improving histopathological outcomes in the chondrocytes of OA rats.
Conclusions:
Treatment with miR-106a mimic ameliorates inflammation in cartilage tissues of OA subjects by activating death receptor 6 via the NF-κB signalling pathway.
Insights
MicroRNA-106a mimics reduce inflammation and apoptosis in osteoarthritis models. This study shows miR-106a protects cartilage by activating death receptor 6 through the NF-κB pathway.
Area of Science:
- Biomedical Science
- Molecular Biology
- Pathology
Background:
- Osteoarthritis (OA) is a prevalent inflammatory joint disease marked by cartilage degradation, posing a significant therapeutic challenge.
- Current OA management strategies are limited, necessitating the development of novel treatment approaches.
Purpose of the Study:
- To investigate the potential protective effects of microRNA-106a (miR-106a) mimics in an established murine model of osteoarthritis (OA).
Main Methods:
- Utilized both in vitro (rat chondrocytes) and in vivo (rat OA model) systems to assess miR-106a mimic efficacy.
- Inflammation was induced using lipopolysaccharide (LPS); effects on cytokine production, apoptosis, and protein expression (DR6, NF-κB pathway) were evaluated.
Main Results:
- miR-106a mimic treatment significantly reduced inflammatory cytokine and apoptotic protein levels in LPS-induced inflammation.
- The mimic attenuated the expression of DR6, IκBα, and p65 proteins in chondrocytes and improved histopathological outcomes in the in vivo OA model.
Conclusions:
- miR-106a mimic administration ameliorates inflammation in OA cartilage by activating death receptor 6 (DR6) via the NF-κB signaling pathway.
- These findings highlight miR-106a as a potential therapeutic agent for osteoarthritis treatment.
Related Concept Videos
01:16TGF - β Signaling Pathway
01:20The JAK-STAT Signaling Pathway
01:07MAPK Signaling Cascades